Please login to the form below

Not currently logged in
Email:
Password:

Sensipar

This page shows the latest Sensipar news and features for those working in and with pharma, biotech and healthcare.

Amgen’s R&D chief Sean Harper retires to seek biotech post

Amgen’s R&D chief Sean Harper retires to seek biotech post

Bradway said two new products – Aimovig (erenumab) for migraine and Sensipar follow-up Parsabiv (etelcalcetide) for chronic kidney disease – had started well, and the quarter was also marked by the launch

Latest news

  • NICE set to back Parsabiv for kidney disease complication NICE set to back Parsabiv for kidney disease complication

    be treated with Amgen's older drug Sensipar/Mimpara (cinacalcet) - and provided Amgen supplies the drug at an agreed discount. ... exceed Sensipar's sales at its peak, although rising levels of payer pushback in the US and elsewhere has led others to

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Amgen's chronic kidney disease drug Parsabiv cleared in US. Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... to be used in clinical practice, the monthly costs of Parsabiv and Sensipar should be comparable.".

  • Amgen wins European approval for Parsabiv Amgen wins European approval for Parsabiv

    Prior to that Parsabiv had been predicted to equal and potentially exceed Sensipar, which brought in more than $1.4bn last year, although it is starting to face  generic competition in ... Amgen says Sensipar only has around 25% market penetration,

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    FDA knocks back Amgen's chronic kidney disease treatment. Parsabiv was hoped to equal or exceed solid earner Sensipar. ... Sadly, Amgen failed to show that Sensipar could reduce the risk of death and cardiovascular events in patients in CKD patients on

  • Amgen's Sensipar follow-up clears phase III trial Amgen's Sensipar follow-up clears phase III trial

    Amgen's Sensipar follow-up clears phase III trial. AMG 416 meets objectives in hyperparathyroidism. ... One of the unsung heroes in Amgen's product portfolio is Sensipar/Mimpara for secondary hyperparathyroidism (HPT), which has grown fairly steadily

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics